Financials data is unavailable for this security.
View more
Year on year Gland Pharma Ltd had little change in net income (from 7.81bn to 7.72bn) despite revenues that grew 56.29% from 36.25bn to 56.65bn. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 22.35% to 35.53%.
| Gross margin | 60.30% |
|---|---|
| Net profit margin | 11.74% |
| Operating margin | 15.16% |
| Return on assets | 6.54% |
|---|---|
| Return on equity | 8.09% |
| Return on investment | 7.65% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Gland Pharma Ltd fell by 15.52bn. However, the company earned 9.97bn from its operations for a Cash Flow Margin of 17.60%. In addition the company used 17.57bn on investing activities and also paid 7.99bn in financing cash flows.
| Cash flow per share | 65.28 |
|---|---|
| Price/Cash flow per share | 27.38 |
| Book value per share | 533.41 |
|---|---|
| Tangible book value per share | 511.24 |
More ▼
Balance sheet in INRView more
| Current ratio | 4.16 |
|---|---|
| Quick ratio | 3.14 |
| Total debt/total equity | 0.0372 |
|---|---|
| Total debt/total capital | 0.0358 |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -1.13%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 47.63% |
| EPS growth(5 years) | 11.12 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1.01 |
More ▼
